Organisation
Laboratory of Translational Genetics (VIB-KU Leuven)
Division
The overall aim of the research of the Laboratory of Translational Genetics, is to unravel the genetic predisposition to cancer and to annotate somatic changes in solid tumors with the ultimate aim to discover and functionally validate genetic biomarkers for cancer therapies.
Current researchers
1 - 10 of 10 results
- Diether Lambrechts (Responsible)
- Ayse Bassez (Member)
- Dóra Bihary (Member)
- Amelie Franken (Member)
- Diether Lambrechts (Member)
- Aurelie Mechels (Member)
- Junbin Qian (Member)
- Pierre Van Mol (Member)
- Sam Vanmassenhove (Member)
- Jieyi Xiong (Member)
Projects
1 - 10 of 64
- A single-cell approach to identify biomarkers of efficacy and toxicity for immune checkpoint blockade combinations in non-small cell lung cancerFrom5 Oct 2021 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Multiomic Integration of cell-free DNA profiles to Advance Disease OutcomeFrom1 Oct 2021 → TodayFunding: FWO Strategic Basic Research (SBO)
- Connecting Single-cell Immune Profiling in Peripheral Blood with Intratumoral T Cell Expansion in Breast Cancer Upon Checkpoint ImmunotherapyFrom24 Aug 2021 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Developing personalized treatment for advanced penile cancer trough establishment of Patient-Derived Tumor Xenografts (PDTXs).From9 Aug 2021 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Alternative RNA splicing as a predictor of response to checkpoint immunotherapyFrom1 Mar 2021 → TodayFunding: Foundations, funds and other with scientific goal
- Exploring the reciprocal crosstalk between the vasculature in cancer to improve immunotherapyFrom15 Feb 2021 → TodayFunding: Foundations, funds and other with scientific goal
- Single-cell omics data analysis in translational oncologyFrom1 Feb 2021 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- EU-Genomics: EU Infrastructure for Genome AnalysisFrom1 Jan 2021 → TodayFunding: FWO Large scale research infrastructure
- Epigenetic and Spatial Single-cell profiling in the context of Cancer ImmunotherapyFrom1 Jan 2021 → TodayFunding: FWO research project
- Defining (epi)genomic transition from precursor lesion to invasive rare ovarian cancerDefining (epi)genomic transition from precursor lesion to invasive rare ovarian cancerFrom1 Apr 2020 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
Publications
1 - 10 of 559
- Molecular Heterogeneity Between Paired Primary and Metastatic Lesions from Clear Cell Renal Cell Carcinoma.(2022)
Authors: Eduard Roussel, Lisa Kinget, Diether Lambrechts
Pages: 54 - 57 - PHGDH heterogeneity potentiates cancer cell dissemination and metastasis.(2022)
Authors: Margherita Demicco, Ginevra Doglioni, Anke Vandekeere, Juan Fernandez Garcia, David Nittner, Francesca Rizzollo, Panagiotis Karras, Dorien Broekaert, Sofie Demeyer, Ayse Bassez, et al.
Pages: 747 - 753 - Nucleosome footprinting in plasma cell-free DNA for the pre-surgical diagnosis of ovarian cancer(2022)
Authors: An Coosemans, Toon Van Gorp, Tom Venken, Ruben Heremans, Thomas Holland Bourne, Ben Van Calster, Diether Lambrechts
Number of pages: 9 - Determinants of 25-hydroxyvitamin D Status in a Cutaneous Melanoma Population.(2022)
Authors: Julie De Smedt, Laudine Janssen, Dirk Vanderschueren, Kris Bogaerts, Oliver Bechter, Jaak Billen, Diether Lambrechts, Maria Garmyn
Pages: adv00692 - Antizyme Inhibitor 1 Regulates Matrikine Expression and Enhances the Metastatic Potential of Aggressive Primary Prostate Cancer(2022)
Authors: Lisa Moris, Diether Lambrechts, Christine Helsen, Bart Ghesquière, Stefaan Soenen, Roy Eerlings, Sarah El Kharraz, Hendrik Van Poppel, Steven Joniau, Frank Claessens
Pages: 527 - 541Number of pages: 15 - CA-125 Levels Are Predictive of Survival in Low-Grade Serous Ovarian Cancer-A Multicenter Analysis(2022)
Authors: Diether Lambrechts
Number of pages: 12 - Randomized CLIO/BGOG-ov10 trial of olaparib monotherapy versus physician's choice chemotherapy in relapsed ovarian cancer.(2022)
Authors: Els Van Nieuwenhuysen, Sileny Han, Siel Olbrecht, Patrick Neven, Diether Lambrechts, Toon Van Gorp, Ignace Vergote
Pages: 14 - 22 - European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer(2022)
Authors: Ignace Vergote, Diether Lambrechts
Pages: 276 - 287Number of pages: 12 - Organoids from human tooth showing epithelial stemness phenotype and differentiation potential(2022)
Authors: Lara Hemeryck, Florian Hermans, Diether Lambrechts, Hugo Vankelecom
Number of pages: 23 - c-MET/VEGFR-2 co-localisation impacts on survival following bevacizumab therapy in epithelial ovarian cancer: an exploratory biomarker study of the phase 3 ICON7 trial(2022)
Authors: Diether Lambrechts
Number of pages: 11